source
- Alumis' TYK2 inhibitor flunks mid-stage lupus trial, shares drop 55%Alumis reported that its experimental TYK2 inhibitor, envudeucitinib, failed to meet any primary or secondary endpoints in a mid-stage study of systemic lupus erythematosus. The company highlighte…
- Novartis reports Phase 3 success for MS pill remibrutinib, beats Aubagio and shows no liver safety issuesNovartis announced that its BTK inhibitor remibrutinib met primary endpoints in two Phase 3 trials in patients with relapsing multiple sclerosis. The studies showed the drug reduced annualized rel…